1. Successful pregnancy and delivery in a patient with chronic myelogenous leukemia (CML), and management of CML with leukapheresis during pregnancy: a case report and review of the literature
- Author
-
Fahir Özkalemkaş, Ülkü Ozan, Vildan Ozkocaman, Yalçın Kimya, Ahmet Tunali, Tulay Ozcelik, Rıdvan Ali, Uludağ Üniversitesi/Tıp Fakültesi/İç hastalıkları Anabilim Dalı., Uludağ Üniversitesi/Tıp Fakültesi/Kadın Hastalıkları ve Doğum Anabilim Dalı., Ali, Rıdvan, Özkalemkaş, Fahri, Özkocaman, Vildan, Özçelik, Tülay, Ozan, Ülkü, Kimya, Yalçın, Tunalı, Ahmet, AAG-8495-2021, and AAH-1854-2021
- Subjects
Adult ,Cancer Research ,Pediatrics ,medicine.medical_specialty ,Cells ,Myelogenous ,Chronic myelocytic-leukemia ,Pregnancy ,hemic and lymphatic diseases ,Leukemia, Myelogenous, Chronic, BCR-ABL Positive ,Medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,Leukapheresis ,Chromosomal-abnormalities ,Chronic myeloid-leukemia ,business.industry ,Imatinib ,General Medicine ,medicine.disease ,Delivery, Obstetric ,Surgery ,Imatinib mesylate ,Leukemia ,Oncology ,Gestation ,Female ,Therapy ,business ,Pregnancy Complications, Neoplastic ,Chronic myelogenous leukemia ,Alpha-interferon ,Hydroxyurea treatment ,medicine.drug - Abstract
Although infrequently seen, the management of cancer during pregnancy can be difficult for patients, their families and physicians. The concomitant occurrence of pregnancy and chronic myelogenous leukemia is uncommon. We describe the successful management of a 26-year-old woman in the first trimester of her pregnancy with chronic myelogenous leukemia (CML) in chronic phase by using only leukapheresis. She was treated with leukapheresis until her delivery at 36 weeks of gestation. The procedure was without significant adverse effects on the patient or fetus. We applied a total of 15 leukapheresis treatments throughout the pregnancy. The patient gave birth vaginally to a healthy 2800 g boy at 36 weeks of gestation. We conclude that leukapheresis may provide an alternative treatment to chemotherapy, alpha-interferon or imatinib in pregnant patients with CML, particularly with concern over their potential teratogenic and other adverse effects.
- Published
- 2004